AN2 Therapeutics, Inc. (ANTX) stock
ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.23−0.24 (-5.37%)
Close on Nov 17, 2026Market cap $159.62MP/E –Yield –
AN2 Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
AN2 Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$30.68M. For fiscal 2025 it was -$29.83M. The highest annual figure on record is -$20.48M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$29.83M | – |
| FY2024 | Dec 31, 2024 | -$49.26M | – |
| FY2023 | Dec 31, 2023 | -$53.29M | – |
| FY2022 | Dec 31, 2022 | -$33.46M | – |
| FY2021 | Dec 31, 2021 | -$20.48M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.38M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.27M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.59M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.60M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.49M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.60M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.99M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.26M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.54M | – |
See a number that looks wrong?